The remarkable yin and yang of tumour hypoxia

International Journal of Radiation Biology

Volumn 86, Issue 11, 2010, Pages 907-917

  Brown, Martin ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

angiogenesis; hypoxia; macrophages; radiosensitizers; tumour physiology; vascular system

Indexed keywords

CYTOTOXIN; ETANIDAZOLE; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1; MISONIDAZOLE; OXYGEN; TIRAPAZAMINE; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; CANCER CELL; CANCER RADIOTHERAPY; CELL KILLING; CELL SURVIVAL; CHEMICAL STRUCTURE; CONFERENCE PAPER; HEMATOPOIETIC STEM CELL; HYPOXIA; HYPOXIC CELL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; SOLID TUMOR; STEREOTACTIC BODY RADIATION THERAPY; TISSUE OXYGENATION; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR HYPOXIA; TUMOR VASCULARIZATION; ANOXIA; ARTICLE; AWARDS AND PRIZES; CELL HYPOXIA; DRUG EFFECT; HISTORY; HUMAN; MALE; METABOLISM; METHODOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); ONCOLOGY; PATHOPHYSIOLOGY; PERSONNEL; PHYSIOLOGY; RADIATION EXPOSURE;

ANOXIA; ANTINEOPLASTIC AGENTS; AWARDS AND PRIZES; CELL HYPOXIA; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION ONCOLOGY; RESEARCH PERSONNEL;

EID: 78049472777     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2010.492492     Document Type: Conference Paper

References (55)

1. AhnGO, Brown JM. 2008.Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for an giogenesis: Role of bone marrow-derived myelomonocytic cells. Cancer Cell 13:193-205.
2. Alper T, Howard-Flanders P. 1956. Role of oxygen in modifying the radiosensitivity of E. coli B. Nature 178:978-979.
3. Anderson RF, Shinde SS, HayMP, Gamage SA, DennyWA. 2003. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. Journal of American Chemical Society 125:748-756.
4. Asahara T, Murohara T, Sullivan A, Silver M, Van Der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967.
5. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. 1999. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiotherapy and Oncology 53:113-117.
6. Brown JM. 1975. Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro 7-0582. Radiation Research 64:633-647.
7. Brown JM. 1977. Cytotoxic effects of the hypoxic cell radiosensitizer Ro 7-0582 to tumor cells in vivo. Radiation Research 72:469-486.
8. Brown JM. 1979. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. British Journal of Radiology 52:650-656.
9. Brown JM. 2000. Exploiting the hypoxic cancer cell:Mechanisms and therapeutic strategies. MolecularMedicine Today 6:157-162.
10. Brown JM. 2007. Tumor hypoxia in cancer therapy. Methods in Enzymology 435:298-321.
11. Brown JM, Yu NY, Brown DM, Lee WW. 1981. SR-2508: A 2- nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. International Journal of Radiation Oncology, Biology, and Physics 7:695-703.
12. Budach W, Taghian A, Freeman J, Gioioso D, Suit HD. 1993. Impact of stromal sensitivity on radiation response of tumors. Journal of National Cancer Institute 85:988-993.
13. Bussink J, Kaanders JH, Van Der Kogel AJ. 2003. Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exdogenous and endogenous hypoxic cell markers. Radiotherapy and Oncology 67:3-15.
14. Chaplin DJ, Olive PL, Durand RE. 1987. Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Research 47:597-601.
15. Churchill-Davidson I, Foster CA, Thomlinson RH. 1958. Highpressure oxygen and radiotherapy. Medical World Journal 88:125-128.
16. Coffelt SB, Hughes R, Lewis CE. 2009. Tumor-associated macrophages: Effectors of angiogenesis and tumor progression. Biochimestry Biophysics Acta 1796:11-18.
17. Denekamp J, Joiner MC. 1982. The potential benefit from a perfect radiosensitizer and its dependence on reoxygenation. British Journal of Radiology 55:657-663.
18. Dische S, Saunders MI. 1978. Clinical experience with misonidazole. British Journal of Cancer 37:311-313.
19. Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, Treszezamsky A, Chon BH, Feng Z, Gu Y, Wilson WR, Pommier Y, Olive PL, Powell SN, Brown JM. 2008. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Research 68:257-265.
20. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R. 2003. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155-1159.
21. Gerber HP, Mcmurtrey A, Kowalski J, Lyden D, Yan M, Keyt BA, Dixit V, Ferrara N. 1998. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 30-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. Journal of Biological Chemistry 273:30336-30343.
22. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. 1953. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. British Journal of Radiology 26:638-648.
23. Hall EJ, Roizin-Towle L. 1975. Hypoxic sensitizers: Radiobiological studies at the cellular level. Radiolog y 117:453-457.
24. Hay MP, Hicks KO, Pruijn FB, Pchalek K, Siim BG, Wilson WR, Denny WA. 2007. Pharmacokinetic/pharmacodynamic modelguided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: The role of extravascular transport. Journal of Medicinal Chemistry 50:6392-6404.
25. Hill RP. 1986. Sensitizers and radiation dose fractionation: Results and interpretations. International Journal of Radiation Oncology, Biology, and Physics 12:1049-1054.
26. Hill RP. 1992. Experimental radiotherapy. In: Tannock IF, Hill RP, editors. The basic science of oncology. 2nd ed. Toronto: McGraw-Hill, Inc.
27. Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR. 2010. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldoketo reductase 1C3, in patients with solid tumors. Cancer Chemotherapy Pharmacology 65:791-801.
28. Janssen HL, Haustermans KM, Balm AJ, Begg AC. 2005. Hypoxia in head and neck cancer: How much, how important? Head and Neck 27:622-638.
29. Kallman RF. 1972. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 105:135-142.
30. Kaplan HS. 1974. On the relative importance of hypoxic cells for the radiotherapy of human tumours. European Journal of Cancer 10:275-280.
31. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. 2010. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. Journal of Clinical Investigation 120:694-705.
32. Koch CJ. 1993. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Research 53:3992-3997.
33. Lanzen J, Braun RD, Klitzman B, Brizel D, Secomb TW, Dewhirst MW. 2006. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Research 66:2219-2223.
34. Lee D-J, Pajak TF, Marcial VA, Fu KK, Rotman M, Cooper JS, Ortiz HG, Beitler JJ, Abrams RA, Curran WJ, Coleman CN, Wasserman TH. 1995. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. International Journal of Radiation Oncology, Biology, and Physics 32:567-576.
35. Moeller BJ, Cao Y, Li CY, Dewhirst MW. 2004. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429-441.
36. Mohindra JK, Rauth AM. 1976. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Research 36:930-936.
37. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, Hanks GE, Pollack A. 2002. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: Preliminary findings. Urology 60:634-639.
38. Nordsmark M, Bentzen SM, Overgaard J. 1994. Measurement of human tumour oxygenation status by a polarographic needle electrode. Acta Oncology 33:383-389.
39. Nordsmark M, Overgaard M, Overgaard J. 1996. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 41:31-40.
40. Overgaard J. 2007. Hypoxic radiosensitization: Adored and ignored. Journal of Clinical Oncology 25:4066-4074.
41. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR. 2007. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clinical Cancer Research 13:3922-3932.
42. Peters LJ, Rischin D, Hicks RJ, Hughes PG, Sizeland AM. 1999. Extraordinary tumor control in phase I trial of concurrent tirapazamine cisplatin and radiotherapy for far advanced head and neck cancer. International Journal of Radiation Oncology, Biology, and Physics 45:148-149 (Abstr #148).
43. Peters LJ, Rischin D, Fisher R, Corry J, Hicks R. 2007. Identification and therapeutic targeting of hypoxia in H&N cancer. Abstract PS1042. International Congress of Radiation Research, San Francisco, July 2007.
44. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B. 2005. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). Journal of Clinical Oncology 23:79-87.
45. Rischin D, Peters L, OSullivan B, Giralt J, Yuen K, Trotti A, Bernier J, Bourhis J, Henke M, Fisher R, Group T-Tro. 2008. Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 26: Abstract 2008 ASCO Annual Meeting Proceedings.
46. Sheldon PW, Foster JL, Fowler JF. 1974. Radiosensitization of C3H mouse mammary tumours by a 2-nitroimidazole drug. British Journal of Cancer 30:560-565.
47. Stone HB, Withers HR. 1975. Enhancement of the radioresponse of a murine tumour by a nitroimidazole. British Journal of Radiology 48:411-412.
48. Suit HD, Sedlacek R, Silver G, Hsieh C-C, Epp ER, Ngo FQH, Roberts WK, Verhey L. 1988. Therapeutic gain factors for fractionated radiation treatment of spontaneous murine tumours using fast neutrons, photons plus O2(1) or 3 ATA, or photons plus misonidazole. Radiation Research 116:482-502.
49. Sutherland RM, Franko AJ. 1980. On the nature of the radiobiologically hypoxic fraction in tumors. International Journal of Radiation Oncology, Biology, and Physics 6:117-120.
50. Thomlinson RH, Gray LH. 1955. The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer 9:539-549.
51. Trotter MJ, Chaplin DJ, Olive PL. 1989. Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. British Journal of Cancer 59:706-709.
52. Wouters BG, Brown JM. 1997. Cells at intermediate oxygen levels can be more important than the hypoxic fraction in determining tumor response to fractionated radiotherapy. Radiation Research 147:541-550.
53. Yamaura H, Matsuzawa T. 1979. Tumor regrowth after irradiation: An experimental approach. International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine 35:201-219.
54. Yang L, Debusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC. 2004. Expansion of myeloid immune suppressor GrCD11bcells in tumorbearing host directly promotes tumor angiogenesis. Cancer Cell 6:409-421.
55. Zagorevskii D, Song M, Breneman C, Yuan Y, Fuchs T, Gates KS, Greenlief CM. 2003. A mass spectrometry study of tirapazamine and its metabolites. Insights into the mechanism of metabolic transformations and the characterization of reaction intermediates. Journal of American Society Mass Spectrometry 14:881-892.